Prostate cancer research from 2010 ASCO conference

The most interesting and notable prostate cancer research from the 2010 ASCO (American Society of Clinical Oncology) conference.

Held in Chicago June 4-8, the annual meeting brought together 50,000 physicians, researchers, and other health care professionals from around the globe to discuss and hear the latest results in cancer research. Click the links to read the articles on the ASCO website.

Androgen Deprivation plus Radiation Therapy May Emerge as New Standard of Care for Locally Advanced Prostate Cancer

Data emerging from a large, randomized international trial suggest that continuous androgen deprivation plus external beam radiation therapy “should be the standard treatment approach” for men with locally advanced prostate cancer, according to participants from Sunday’s Genitourinary (Prostate) Cancer Oral Abstract Session.

Denosumab Superior to Zoledronic Acid for Delaying Skeletal Events in Prostate Cancer

In a large, randomly assigned, double-blind, active-controlled phase III trial of patients with castration-resistant prostate cancer (CRPC) that metastasized to bone, denosumab delayed the time to a skeletal- related event (SRE) by 3.6 months over zoledronic acid.

Stay in the Know

Subscribe to the Navigating Cancer blog for the latest news, innovations, and best practices in oncology care.